![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
An extra-corporeal chamber has been constructed and used for diagnosis, enzyme therapy and immuno-adsorption. The chamber is made from polymethyl-acrylate and the dimensions of the chamber are 10 × 18 × 7 cm. It contains 23 plates with a total area of 0.5 m2. In most cases no pump is used. The active substance is bound covalently to the plate surfaces. The time for each hemoperfusion has been 3–6 hr. No infections, decrease of thrombocytes or other side effects have been observed.
By immobilized homologous antisera (F (ab')2), three putative tumour-associated antigens were isolated from cages of hypernephroma. Two children and one adult patient with malignant lymphoma were treated with extra-corporeal L-asparaginase, the latter with repeated remissions of metastases.
The level of antibodies against Factor VIII was significantly decreased by chamber immunoadsorption in two cases of hemophilia. A number of kidney transplantation cases received extra-corporeal L-asparaginase pre- and post-operatively to counteract rejection. In all around 50 patients have received extra-corporeal treatment without any adverse effects. The use of the extra-corporeal chamber in other diseases is discussed.